Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications TCR T Cells G-Rex®24 Well Plate

Publication Date: September 23, 2025

A TGF-βR/IL-2R immunomodulatory fusion protein transforms immunosuppression into T cell activation to enhance adoptive T cell therapy

Engineered TGF-β receptor/IL-2 receptor fusion proteins (IFPs) let human CD8+ T cells turn the immunosuppressive cytokine TGF-β1 into an IL-2-like proliferative signal. Of four designs tested, two (1β2γ and 2β1γ) gave the strongest STAT5 phosphorylation after TGF-β1 exposure, while reducing SMAD2/3 signaling at higher TGF-β1 doses. IFP-expressing cells proliferated in TGF-β1, and nearly 100% of cells expressed the IFP by day 7 at 25 ng/mL. In PANC-1 cocultures with mesothelin-specific TCR T cells and 10 ng/mL TGF-β1, adding the IFP improved tumor killing at 20:1 and 10:1 ratios and T cell expansion. After two weeks of chronic tumor exposure with TGF-β1, IFP cells better maintained effecto…

Download Now →

Author: Yapeng Su, Ashley Thelen +6 more

Publications Other

Publication Date: September 23, 2025

Postapproval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy Products

This FDA draft guidance describes how sponsors can collect safety and efficacy data on cell and gene therapy products after approval, because pre-approval trials usually treat few patients and these products may act for many years. It discusses real-world data from electronic health records, medical claims and vital statistics, noting limits such as missing rare-disease variables, fragmented records and low statistical power. It also covers registries, including Coordinated Registry Networks, which can capture longitudinal, patient-reported and genetic data, and decentralized data collection using local clinicians, telemedicine and remote visits. Sponsors are advised to protect patient da…

Download Now →

Author: U.S. Department of Health and Human Services, Food and Drug Administration +1 more

Publications Other

Publication Date: September 23, 2025

Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations

This FDA draft guidance recommends innovative clinical trial designs for cell and gene therapy products aimed at small populations, generally rare diseases, to generate evidence supporting licensure. It describes six approaches: single-arm trials in which participants serve as their own baseline control, disease progression modeling, externally controlled studies using historical or real-world data, adaptive designs such as group sequential, sample size reassessment, enrichment and dose-selection, Bayesian designs that borrow external data, and master protocols including platform, umbrella and basket trials. It also advises on participant selection, covering treatment landscape, symptom s…

Download Now →

Author: U.S. Department of Health and Human Services, Food and Drug Administration +1 more

Publications CD34 Cells

Publication Date: September 23, 2025

Expedited Programs for Regenerative Medicine Therapies for Serious Conditions

FDA's September 2025 draft guidance explains how sponsors of regenerative medicine therapies for serious conditions can use expedited programs: fast track, breakthrough therapy, RMAT designation, priority review and accelerated approval. A therapy qualifies for RMAT designation if it meets the regenerative medicine definition, is intended to treat, modify, reverse or cure a serious condition, and preliminary clinical evidence suggests it can address unmet medical needs. CBER notifies the sponsor within 60 calendar days of a designation request. Priority review carries a 6-month goal for reviewing the application. RMAT products may receive accelerated approval, and post-approval requiremen…

Download Now →

Author: U.S. Department of Health and Human Services, Food and Drug Administration +1 more

Publications CAR T Cells G-Rex®24 Well Plate

Publication Date: September 22, 2025

Lentiviral-mediated panErbB CAR-T cell therapy against head and neck squamous cell carcinomas for patients with Fanconi anemia

Lentiviral panErbB CAR-T cells can be manufactured from patients with Fanconi anemia as efficiently as from healthy donors and kill head and neck squamous cell carcinoma in mice. The second-generation T1E CAR with a 4-1BB domain was transduced at an MOI of 10 TU/cell into activated PBMNCs, which were expanded for 10 days in G-Rex® 24-well plates with IL-7 and IL-15. Mean viability exceeded 70%, expansion exceeded 50-fold, CAR-T cells reached around 75%, and vector copy number was around 2 per cell, regardless of donor type. In vitro, the cells were cytotoxic against FA-proficient and FA-deficient HNSCC cell lines. A single intratumoral dose of 15 million HD CAR-T cells controlled VU-1131…

Download Now →

Author: Andrea López, David Charbonnier +19 more

Publications CAR T Cells, Other

Publication Date: September 17, 2025

Cryopreserved G-CSF-Mobilized Apheresis Units in ATMP Manufacturing

Cryopreserved G-CSF-mobilized apheresis units, originally banked for donor lymphocyte infusion, can serve as a ready-to-use starting material for manufacturing cytokine-induced killer (CIK) cells. After thawing, automated washing on the LOVO system gave significantly higher cell recovery than manual washing, with comparable viability. Cells from three LOVO-washed units reached the full target dose of the clinical protocol. Lot-release compliance resembled that of products from fresh blood or lymphocyte apheresis. Culture in G-Rex® bioreactors for 9-12 days gave higher expansion than flask culture for 21-26 days, with similar phenotype. Preliminary CAR-CIK production by electroporation als…

Download Now →

Author: E. Gotti, S. Panna +6 more

Publications NK Cells G-Rex®6 Well Plate

Publication Date: September 5, 2025

A Scalable Protocol for Ex Vivo Production of CAR-Engineered Human NK Cells

A step-by-step protocol is described for making CAR-NK cells from human peripheral blood, covering PBMC isolation, CD3 depletion and CD56 selection of NK cells, lentiviral CAR transduction, and expansion in G-Rex® culture. Isolated NK cells reached over 90% purity and over 95% viability. Activation with K562 feeder cells gave higher CAR expression than feeder-free PMA/ionomycin activation, while CD25 and PD-1 levels were comparable. After 14 days of expansion, CAR-NK cells grew more than 15-fold with either method, with viability above 70% at all time points. Cell viability did not differ significantly between pre-freeze and post-thaw samples after 24 h at -80 °C. Transduction efficiency…

Download Now →

Author: Supreet Khanal, Nirjal Bhattarai

Publications γδ T G-Rex®6 Well Plate, G-Rex®6M Well Plate

Publication Date: September 4, 2025

Allogeneic Polyclonal CD38KO/CD38-CAR γδT Cells For The Treatment Of T Cell Malignancies

Polyclonal γδT cells from healthy donors were expanded with a short pan-γδTCR antibody stimulation followed by mbIL21/41BBL feeder cells, then edited by CRISPR/AAV to knock out CD38 and insert a CD38-targeting CAR at the same locus, which prevented fratricide. The hybrid expansion gave roughly 10-fold higher yield in two weeks than feeder cells alone, and αβT cells fell from 64.4% to 0.3%. CAR expression averaged 38% with the hybrid system. Edited cells outperformed unedited γδT cells against three baseline and two relapsed patient T-ALL samples, and in Jurkat-bearing NSG mice a single dose markedly reduced leukemia burden in blood, bone marrow and spleen without cytokine support.

Download Now →

Author: Genesis Snyder, Yasemin Sezgin +15 more

Publications CAR T Cells G-Rex®24 Well Plate

Publication Date: September 3, 2025

CAR T cell engineering impacts antigen-independent activation and co-inhibition

Sleeping beauty (SB) transposition can produce CAR T cells against the CLL neoepitope IGLV3-21 R110 with transgene expression similar to lentiviral (LV) manufacturing, but the products differ in phenotype. In a head-to-head comparison using healthy-donor and CLL-patient T cells, about 40% of cells expressed the CAR two weeks after manipulation. SB products shifted toward CD8+ cells with a naive-like phenotype, yet showed higher CD69 and LAG-3 without antigen exposure. Single-cell sequencing revealed inflammatory RIG-I and TLR nucleic-acid-sensing signatures in SB products. The CLL-patient product, a single donor, had fewer CAR-positive cells, fewer proliferating clusters and lower TCR div…

Download Now →

Author: Christoph Schultheiß, Simon Stücheli +10 more

Publications CAR T Cells

Publication Date: August 18, 2025

Proof of concept of a fully enclosed CAR-T process without use of a biosafety cabinet

CellSeal Connect closed vials performed comparably to standard cryovials for storing starting T cells and lentiviral vector in a CAR-T process, supporting manufacture without a biosafety cabinet. Enriched CD4/CD8 T cells from three healthy donors were cryopreserved in either container, thawed, activated, transduced with an anti-CD19 CAR/GFP lentiviral vector at an MOI of 1.9 and expanded for seven days. Fold expansion was 38.8, 34.6 and 37.8 with CellSeal Connect versus 33.4, 39.9 and 34.5 with cryovials, and transduction was 43 to 54% versus 46 to 59%. Viability stayed high at all time points in all donors. Final product frozen in CellSeal CryoCases had post-thaw viability of 94.8 to 96.…

Download Now →

Author: Jon Pileggi, Menna Siddiqui +7 more

Publications Treg Cells G-Rex®6 Well Plate

Publication Date: August 14, 2025

HLA-A2 CAR/IL-2-CISC engineered Treg display robust in vitro and in vivo antigen-specific regulatory function

Engineered regulatory T cells made from CD4+ T cells with an HLA-A2-specific CAR and an IL-2 signaling complex protected mice from xenogeneic graft-versus-host disease more effectively than polyclonal engineered Tregs. The products expanded about 15- to 30-fold in G-Rex® culture. In vitro, A2CAR expression did not compromise the Treg phenotype or suppressive capacity, and these cells killed A2-positive target cells significantly less than A2CAR effector T cells. In mice given A2-positive PBMCs, all recipients of A2CAR EngTreg survived to the study endpoint, whereas polyclonal EngTreg recipients did not differ in survival from PBMC-only controls. At sub-therapeutic doses, the rapamycin ana…

Download Now →

Author: Subhash K. Tripathi, Annaiz Grimm +6 more

Publications NKT Cells G-Rex®6M Well Plate

Publication Date: August 12, 2025

Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells

Allogeneic mesothelin-targeting CAR-NKT cells generated from cord blood CD34+ stem and progenitor cells outperformed conventional CAR-T cells against ovarian cancer in preclinical models. Cells from a 6-week culture reached nearly 100% CAR co-expression, and one cord blood donor was estimated to yield about 1,000 to 10,000 doses. In OVCAR8 xenograft mice, IL-15-enhanced CAR-NKT cells given intraperitoneally eradicated tumors in five of six animals with survival beyond 150 days. They killed antigen-negative tumor cells, depleted CD1d-high tumor-associated macrophages, lowered cytokine release syndrome markers, and caused no graft-versus-host disease. Low surface HLA expression helped them…

Download Now →

Author: Yan-Ruide Li, Zhe Li +39 more